Drug General Information (ID: DDIHJWB8OF)
  Drug Name Bivalirudin Drug Info Heparin Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antithrombotic Agents Anticoagulants
  Structure

 Mechanism of Bivalirudin-Heparin Interaction (Severity Level: Major)
     Increased risk of bleeding Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Bivalirudin Heparin
      Mechanism Risk of bleeding
Anticoagulant 
Risk of bleeding
Anticoagulant 
      Key Mechanism Factor 1
Factor Name Bleeding
Factor Description Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
      Mechanism Description
  • Increased risk of bleeding by the combination of Bivalirudin and Heparin 

Recommended Action
      Management Until further data are available, coadministration of bivalirudin and all anticoagulants should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.

References
1 Product Information. Angiomax (bivalirudin) The Medicines Compny, Cambridge, MA.